Craig E Cole MD
Clotting Disorder, Hematologic Oncology
Gundersen Lutheran center for cancer and blood disorders
Join to View Full Profile
401 W Greenlawn AveLansing, MI 48910
Phone+1 517-975-9500
Fax+1 517-975-9520
Dr. Cole is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2001- University of MichiganResidency, Internal Medicine, 1999
- University of MichiganInternship, Internal Medicine, 1995 - 1996
Ohio State University College of MedicineClass of 1995
Certifications & Licensure
MI State Medical License 1995 - 2026
IA State Medical License 2010 - 2014
MN State Medical License 2010 - 2014
WI State Medical License 2003 - 2013
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012-2014, 2016-2017
Publications & Presentations
PubMed
- 5 citationsElotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2025-03-11 - 3 citationsClinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review.Francesca Gay, Elena Zamagni, Craig Emmitt Cole, Christof Scheid, Malin Hultcrantz
Frontiers in Oncology. 2025-01-01 - 13 citationsDisparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.Rahul Banerjee, Yelak Biru, Craig E Cole, Beth Faiman, Shonali Midha
Blood Cancer Journal. 2024-08-27
Abstracts/Posters
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...Craig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma PatientsCraig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM StudyCraig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
We Need More Black Patients in Multiple Myeloma Clinical TrialsMarch 17th, 2025- Exercise: A Prescription for Almost Any ConditionSeptember 14th, 2022
- This May Be Democrats’ Best Chance to Lower Drug PricesOctober 27th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
